Navigation Links
New Report by BioTrends Examines the Treatment of Renal Anemia in China
Date:10/6/2010

EXTON, Pa., Oct. 6 /PRNewswire/ -- BioTrends Research Group, Inc. recently published its TreatmentTrends®: Renal Anemia in China report. This report is based on survey results from 150 nephrologists in clinical practice in China and qualitative interviews conducted with ten thought leaders in nephrology.  The report examines the demographics of nephrology practice in China and focuses specifically on the management of renal anemia amongst dialysis and later stage chronic kidney disease (CKD) patients.

Earlier diagnosis of renal insufficiency is leading to a rapid increase in the number of patients being seen by nephrologists, however there were numerous mentions about the disparity of care across regions.  Although the majority of nephrologists suggested that economics were not an impediment to treatment with erythropoietin (EPO) products, only about one-third of those surveyed felt that renal anemia management was optimal in China.  Further, 86 percent of those surveyed agreed that the treatment of anemia should begin earlier in CKD than it does in current clinical practice.  The current EPO market is dominated by short acting EPO agents manufactured by local companies, but more than 70 percent report that an EPO agent with a longer dose interval would be highly desirable in a new EPO product. In fact, 44 percent of the surveyed nephrologists reported that there is a high need for new EPO products and that this need is greater than the unmet need for other therapies such as agents for acute renal failure, hyperphosphatemia and lupus nephritis.

The use of intravenous iron products is also prevalent amongst hemodialysis patients, although the use of oral iron (alone or in combination with i.v. iron) is higher in China as compared to other markets.  Similar to the US and EU markets, surveyed nephrologists report prescribing a low dose, consistent maintenance course of iron in hemodialysis patients as opposed to high dose, infrequent repletion therapy.  Iron sucrose (brand name: Venofer) was noted as the market share leader in both the dialysis and CKD (non-dialysis) settings and the respondents reported very high satisfaction with this agent compared to other brands.  The perceived need for new i.v. iron products was rated significantly lower than the need for new EPO agents.

About BioTrends Research Group, Inc.BioTrends Research Group, Inc. provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets.   For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.For more information, contact:BioTrends Research Group, Inc.Decision Resources, Inc.Sharon Funk

Christopher Comfort404-223-2963

781-993-2597 sfunk@bio-trends.com

ccomfort@dresources.com
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Healthcare Providers Rate Elektas MOSAIQ Oncology Information System as No. 1 in 2010 KLAS Report
2. ISTA Pharmaceuticals Reports Positive Preliminary Results from its Phase 1/2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
3. Gerresheimer Reports Strong Earnings and Sales Growth
4. Reportlinker Adds Global Vertebral Compression Fracture Devices Industry
5. Reportlinker Adds Nanobiotechnologies - Applications, Markets and Companies
6. Reportlinker Adds US Pharmaceutical Market Overview - Healthcare reform, economic pressures and the patent cliff set to impact Pharma
7. Reportlinker Adds Antidiabetics Market Forecast
8. Reportlinker Adds Global Anti-CD20 Monoclonal Antibodies Industry
9. Reportlinker Adds Global Intravenous (IV) Iron Drugs Industry
10. Reportlinker Adds Global Sleeping Pills Industry
11. Reportlinker Adds Global Immunoassay Systems Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
(Date:4/19/2017)... -- Cardiology devices segment is anticipated to reach the highest ... Devices segment is likely to create absolute $ opportunity of ... 2017. By the end of 2027, Cardiology Devices segment is ... Mn, expanding at a CAGR of 18.4% over the forecast ... Pacific reprocessed medical devices market in terms of ...
(Date:4/19/2017)... , April 19, 2017 Global Surgical Drainage ... are tubes used to remove excess liquid and air. ... pus, urine, bile or lymph. Surgical drains are used ... such as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery ... post-surgery to prevent accumulation of fluid e.g. blood or ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... 26, 2017 , ... RawTrition now brings you BioEnergy which is a powder ... , RawTrition is taking nutrients to the next level! The superfoods ... its raw form (unlike the synthetically made options that are on the market). , ...
(Date:4/25/2017)... ... ... Bellus Medical, a leader in medical aesthetics, recently acquired ... photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically formulated to ... minimize the appearance of pores – all with minimal downtime and results that ...
(Date:4/25/2017)... IN (PRWEB) , ... April 25, 2017 , ... ... D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration could ... Financial will provide insight into what changes are most likely to make it ...
(Date:4/25/2017)... Switzerland (PRWEB) , ... April 25, 2017 , ... ... innovation targets, they rely on contracted partners to help with process innovation in ... of combined drug formulation experience along with state-of-the-art analytical equipment in support of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a leading ... patient care management module. Using this new feature, sleep physicians can now predict ... on continuous positive airway pressure (CPAP), oral, or other forms of sleep apnea ...
Breaking Medicine News(10 mins):